Lung ultrasound score as a tool to monitor disease progression and detect ventilator-associated pneumonia during COVID-19-associated ARDS.


Journal

Heart & lung : the journal of critical care
ISSN: 1527-3288
Titre abrégé: Heart Lung
Pays: United States
ID NLM: 0330057

Informations de publication

Date de publication:
Historique:
received: 08 03 2021
revised: 28 04 2021
accepted: 04 05 2021
pubmed: 10 6 2021
medline: 5 8 2021
entrez: 9 6 2021
Statut: ppublish

Résumé

Lung ultrasound can accurately detect pandemic coronavirus disease (COVID-19) pulmonary lesions. A lung ultrasound score (LUS) was developed to improve reproducibility of the technique. To evaluate the clinical value of LUS monitoring to guide COVID-19-associated acute respiratory distress syndrome (ARDS) management. We conducted a single center, prospective observational study, including all patients admitted with COVID-19-associated ARDS between March and April 2020. A systematic daily LUS evaluation was performed. Thirty-three consecutive patients were included. LUS was significantly and negatively correlated to P In conclusion, our study demonstrates that LUS variations are correlated to disease severity and progression, and LUS monitoring could contribute to the early diagnosis of VAPs.

Sections du résumé

BACKGROUND
Lung ultrasound can accurately detect pandemic coronavirus disease (COVID-19) pulmonary lesions. A lung ultrasound score (LUS) was developed to improve reproducibility of the technique.
OBJECTIVES
To evaluate the clinical value of LUS monitoring to guide COVID-19-associated acute respiratory distress syndrome (ARDS) management.
METHODS
We conducted a single center, prospective observational study, including all patients admitted with COVID-19-associated ARDS between March and April 2020. A systematic daily LUS evaluation was performed.
RESULTS
Thirty-three consecutive patients were included. LUS was significantly and negatively correlated to P
CONCLUSIONS
In conclusion, our study demonstrates that LUS variations are correlated to disease severity and progression, and LUS monitoring could contribute to the early diagnosis of VAPs.

Identifiants

pubmed: 34107394
pii: S0147-9563(21)00178-3
doi: 10.1016/j.hrtlng.2021.05.003
pmc: PMC8165084
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

700-705

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Références

Medicina (Kaunas). 2021 Jan 20;57(2):
pubmed: 33498180
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Intensive Care Med. 2016 May;42(5):686-698
pubmed: 27033882
Am J Respir Crit Care Med. 2021 Apr 15;203(8):1025-1027
pubmed: 33560931
Acad Radiol. 2020 May;27(5):603-608
pubmed: 32204987
BMC Pulm Med. 2015 Aug 23;15:98
pubmed: 26298866
Crit Care Med. 2010 Jan;38(1):84-92
pubmed: 19633538
Clin Radiol. 2020 Jul;75(7):553-554
pubmed: 32331781
Ultrasound Med Biol. 2020 Aug;46(8):2090-2093
pubmed: 32451194
Ann Transl Med. 2018 Nov;6(21):418
pubmed: 30581826
Am J Respir Crit Care Med. 2018 Aug 1;198(3):398-401
pubmed: 29557671
Intensive Care Med. 2020 May;46(5):849-850
pubmed: 32166346
Chest. 2016 Apr;149(4):969-80
pubmed: 26836896
Am J Respir Crit Care Med. 2011 Feb 1;183(3):341-7
pubmed: 20851923
Crit Care Med. 2012 Jul;40(7):2064-72
pubmed: 22584759
J Crit Care. 2020 Aug;58:65-71
pubmed: 32361220
PLoS One. 2020 Jul 21;15(7):e0236312
pubmed: 32692769
Intensive Care Med. 2021 Feb;47(2):199-207
pubmed: 33392642
Am J Respir Crit Care Med. 2019 Mar 15;199(6):701-714
pubmed: 30372119
Intensive Care Med Exp. 2019 Jul 25;7(Suppl 1):44
pubmed: 31346914
Anaesthesia. 2010 Mar;65(3):294-7
pubmed: 20002364
Intensive Care Med. 2020 Sep;46(9):1761-1763
pubmed: 32451581
J Clin Med. 2019 Aug 11;8(8):
pubmed: 31405211
Heart Lung. 2020 Nov - Dec;49(6):679-680
pubmed: 32861883
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
Respir Med Case Rep. 2021;33:101383
pubmed: 33717868

Auteurs

Auguste Dargent (A)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation, F-69437, Lyon, France. Electronic address: auguste.dargent@chu-lyon.fr.

Emeric Chatelain (E)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation, F-69437, Lyon, France.

Salim Si-Mohamed (S)

Radiology Department, Hospices Civils de Lyon, CHU Louis Pradel, Lyon, France; Claude Bernard Lyon 1 University, INSA-Lyon, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, Lyon, France.

Marie Simon (M)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation, F-69437, Lyon, France.

Thomas Baudry (T)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation, F-69437, Lyon, France.

Louis Kreitmann (L)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation, F-69437, Lyon, France.

Jean-Pierre Quenot (JP)

Médecine Intensive Réanimation, CHU Dijon, 21000 Dijon, France; Université Bourgogne Franche-Comté, LNC, Dijon, France; INSERM, LNC UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France.

Martin Cour (M)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation, F-69437, Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, Faculté de médecine Lyon-Est, F-69373, Lyon, France.

Laurent Argaud (L)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation, F-69437, Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, Faculté de médecine Lyon-Est, F-69373, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH